ACAD
30.46
-0.59
-1.90%
AEMD
0.25
0.00
-1.19%
APRI
1.39
-0.04
-2.80%
ARNA
4.32
-0.2
-4.32%
ATEC
1.29
-0.02
-1.53%
CFN
59.33
-0.28
-0.46%
CNAT
5.82
-0.14
-2.35%
CRXM
0.21
0.00
-1.38%
CYTX
0.48
+0.01
+1.89%
DXCM
59.81
-1.19
-1.95%
GNMK
12.89
-0.42
-3.16%
HALO
14.29
-0.3
-2.06%
ILMN
195.68
-4.32
-2.16%
INNV
0.22
+0.01
+4.19%
INO
8.33
-0.17
-2.00%
ISCO
0.06
0.00
0.00%
ISIS
68.56
-1.3
-1.86%
LGND
56.43
-0.6
-1.05%
LPTN
2.76
-0.09
-3.16%
MBVX
1.04
-0.01
-0.95%
MEIP
3.98
+0.12
+3.11%
MNOV
3.79
+0.02
+0.53%
MRTX
20.67
-0.62
-2.91%
MSTX
0.45
+0.01
+3.37%
NBIX
33.71
-0.64
-1.86%
NUVA
46.31
-0.99
-2.09%
ONCS
0.36
-0.01
-2.74%
ONVO
6.41
-0.28
-4.19%
OREX
5.26
-0.1
-1.78%
OTIC
29.25
-2.32
-7.35%
QDEL
23.53
-0.94
-3.84%
RCPT
110.06
-2.65
-2.35%
RGLS
19.15
+0.57
+3.04%
RMD
62.52
-0.51
-0.81%
SCIE
0.01
0.00
-2.65%
SPHS
0.48
+0.01
+1.34%
SRNE
10.1
-0.68
-6.31%
TROV
6.48
+0.65
+11.17%
VICL
1.03
-0.01
-0.96%
VOLC
17.96
0.00
0.00%
ZGNX
1.36
-0.01
-0.74%
Home » Archive by Category

News

San Diego biotech news from BioSpace, Xconomy, PR Newswire, Marketwired and other sources, click on headlines to read the full story.

Applied Spectral Imaging (ASI) Grabs FDA Approval for GenASIs HiPath Image Capture and Analysis Platform

January 20, 2015 – 5:00 pm | Edit Post

Applied Spectral Imaging (ASI) Receives FDA Clearance for GenASIs™ HiPath IHC Family for HER2, ER, PR and Ki67

CARLSBAD, Calif.–(BUSINESS WIRE)–Applied Spectral Imaging (ASI, www.spectral-imaging.com) announced today that it has received clearance from the U.S. Food and Drug Administration (FDA) for its GenASIs HiPath image capture and analysis platform…

TrovaGene, Inc. Expands Collaboration With Genomac To Demonstrate Clinical Utility In Lung And Colorectal Cancer Treatment Monitoring

January 20, 2015 – 5:00 pm | Edit Post

SAN DIEGO, Jan. 21, 2015 /PRNewswire/ — Trovagene, Inc. (NASDAQ: TROV), today announced it will expand the clinical collaboration with Genomac Research Institute in Prague, Czech Republic. Trovagene Precision Cancer Monitoring SM technology will be us…

Synthetic Genomics, Inc. Release: SGI-DNA Launches Gibson Assembly?? Ultra Kit For Robust, Seamless And Efficient Construction Of Synthetic Genes, Genetic Pathways And Whole Genomes

January 20, 2015 – 5:00 pm | Edit Post

LA JOLLA, Calif., Jan. 21, 2015 /PRNewswire/ –SGI-DNA announces the launch of the Gibson Assembly Ultra Kit which allows researchers to perform complex, large, and multiple fragment assemblies in a simple, two-step reaction.

Cytori Therapeutics, Inc. And Leading Expert Discuss Importance Of “STAR” Trial And Treatment For Scleroderma Patients

January 20, 2015 – 5:00 pm | Edit Post

SAN DIEGO–(BUSINESS WIRE)–Cytori Therapeutics, Inc. (NASDAQ: CYTX) announced today that information, presented last week in San Francisco, introducing its pivotal scleroderma trial (the STAR trial), is now available on the company website at www.Cyto…

Halozyme Therapeutics, Inc. Appoints To Board Of Directors

January 20, 2015 – 5:00 pm | Edit Post

SAN DIEGO, Jan. 21, 2015 /PRNewswire/ –Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced the appointment of Jean-Pierre Bizzari, M.D. to its Board of Directors. Dr. Bizzari brings extensive experience in oncology drug development. “I am delig…

Arena Pharmaceuticals, Inc. Announces Public Offering Of Common Stock

January 20, 2015 – 5:00 pm | Edit Post

SAN DIEGO, Jan. 20, 2015 /PRNewswire/ — Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. All of the shares are being offered by Arena. Jefferies…

In the Jiu-Jitsu Match of Biotech Risk, a Reminder of Other Paths

January 20, 2015 – 4:07 pm | Edit Post
In the Jiu-Jitsu Match of Biotech Risk, a Reminder of Other Paths

Risk makes for great headlines. I’m guilty as charged. My first column for Xconomy questioned whether biotech venture capitalists were losing relevance, running away from risk in an inherently…

[[Click headline to continue reading.]]

In the Jiu-Jitsu Match of Biotech Risk, a Reminder of Other Paths

January 20, 2015 – 4:07 pm | Edit Post

Risk makes for great headlines. I’m guilty as charged. My first column for Xconomy questioned whether biotech venture capitalists were losing relevance, running away from risk in an inherently…

[[Click headline to continue reading.]]

In the Jiu-Jitsu Match of Biotech Risk, a Reminder of Other Paths

January 20, 2015 – 4:07 pm | Edit Post

Risk makes for great headlines. I’m guilty as charged. My first column for Xconomy questioned whether biotech venture capitalists were losing relevance, running away from risk in an inherently…

[[Click headline to continue reading.]]

In the Jiu-Jitsu Match of Biotech Risk, a Reminder of Other Paths

January 20, 2015 – 4:07 pm | Edit Post

Risk makes for great headlines. I’m guilty as charged. My first column for Xconomy questioned whether biotech venture capitalists were losing relevance, running away from risk in an inherently…

[[Click headline to continue reading.]]